MediWound Files Annual Report on Form 20-F

Core Viewpoint - MediWound Ltd. has filed its annual report on Form 20-F for the fiscal year ended December 31, 2025, with the SEC, highlighting its ongoing commitment to transparency and regulatory compliance [2]. Company Overview - MediWound Ltd. is a global biotechnology company specializing in enzymatic, non-surgical therapies for tissue repair [4]. - The company's FDA-approved product, NexoBrid, is used for the enzymatic removal of eschar in thermal burns and is marketed in multiple regions including the United States, European Union, and Japan [4]. - MediWound's late-stage pipeline product, EscharEx, is an investigational therapy aimed at chronic wound debridement, with the potential to set a new standard of care in wound management [4]. Annual Report Details - The annual report on Form 20-F includes audited financial statements and is available for shareholders upon request [3]. - Shareholders can request a hard copy of the annual report via email or post [3].